Cellectis S.A. (NASDAQ:CLLS) Short Interest Down 26.6% in August

Key Points

• Cellectis S.A. experienced a 26.6% decline in short interest during August, bringing the total short interest to 209,600 shares, which is approximately 0.5% of its total shares.
• Wall Street Zen downgraded Cellectis' stock rating from "hold" to "sell"**, although the consensus rating remains a "Buy"** with an average target price of $4.00.
• Despite a reported loss per share of ($0.24) for the recent quarter, Cellectis generated revenue of $18.19 million, exceeding expectations of $10.07 million.

Cellectis S.A. (NASDAQ:CLLS - Get Free Report) was the target of a significant decline in short interest in August. As of August 31st, there was short interest totaling 209,600 shares, a decline of 26.6% from the August 15th total of 285,600 shares. Based on an average daily volume of 152,300 shares, the days-to-cover ratio is currently 1.4 days. Approximately 0.5% of the shares of the stock are sold short. Approximately 0.5% of the shares of the stock are sold short. Based on an average daily volume of 152,300 shares, the days-to-cover ratio is currently 1.4 days.

Analyst Ratings Changes

Separately, Wall Street Zen raised shares of Cellectis to a "hold" rating in a report on Saturday. One equities research analyst has rated the stock with a Buy rating, According to data from MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $4.00.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Millennium Management LLC purchased a new stake in Cellectis during the fourth quarter worth about $962,000. Long Focus Capital Management LLC grew its position in shares of Cellectis by 2.2% during the first quarter. Long Focus Capital Management LLC now owns 4,717,293 shares of the biotechnology company's stock worth $5,849,000 after buying an additional 100,000 shares in the last quarter. OLD Mission Capital LLC acquired a new position in shares of Cellectis during the first quarter worth about $31,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of Cellectis by 228.4% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,722,664 shares of the biotechnology company's stock worth $5,856,000 after buying an additional 3,284,409 shares in the last quarter. Finally, Acadian Asset Management LLC grew its position in shares of Cellectis by 132.9% during the first quarter. Acadian Asset Management LLC now owns 46,377 shares of the biotechnology company's stock worth $55,000 after buying an additional 26,461 shares in the last quarter. Institutional investors and hedge funds own 63.90% of the company's stock.

Cellectis Stock Performance

CLLS traded up $0.28 during trading on Friday, reaching $3.44. 322,112 shares of the company's stock were exchanged, compared to its average volume of 75,601. Cellectis has a 1 year low of $1.10 and a 1 year high of $3.55. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.38 and a quick ratio of 1.38. The stock has a market capitalization of $191.20 million, a P/E ratio of -4.20 and a beta of 3.03. The company's fifty day simple moving average is $2.65 and its 200-day simple moving average is $1.85.

Cellectis (NASDAQ:CLLS - Get Free Report) last posted its quarterly earnings results on Monday, August 4th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.09). The business had revenue of $18.19 million for the quarter, compared to analysts' expectations of $10.07 million. Cellectis had a negative return on equity of 68.05% and a negative net margin of 100.69%. As a group, research analysts predict that Cellectis will post -0.46 earnings per share for the current fiscal year.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.